Antithyroid drugs during breastfeeding.

Area of Science:

• Endocrinology
• Reproductive Medicine
• Neonatal Care

Background:

• Postpartum thyroid dysfunction is increasingly recognized.
• Immune system exacerbations commonly occur 3-12 months after delivery.
• Managing maternal hyperthyroidism during lactation requires careful consideration for both mother and infant.

Purpose of the Study:

• To provide guidance on the safe and effective management of hyperthyroid mothers during lactation.
• To emphasize the safety and benefits of breastfeeding for mothers on antithyroid drugs.
• To outline current expert recommendations for antithyroid drug selection and administration in lactating women.

Main Methods:

• Review of current literature and expert consensus on antithyroid drug use in lactation.
• Analysis of safety profiles and efficacy of different antithyroid drugs (MMI, PTU).
• Guidelines for dosing strategies and monitoring of thyroid function during breastfeeding.

Main Results:

• Continuation or initiation of breastfeeding is safe for hyperthyroid mothers on antithyroid drugs (ATDs).
• Low-to-moderate doses of methimazole (MMI) are recommended as first-line therapy due to concerns about PTU hepatotoxicity.
• Propylthiouracil (PTU) is reserved for severe hyperthyroidism or MMI intolerance.
• Divided ATD doses immediately after feeding and thyroid function monitoring are advised.

Conclusions:

• Breastfeeding should be encouraged in mothers with hyperthyroidism treated with ATDs.
• Methimazole is the preferred antithyroid drug for lactating mothers, with careful dosing and monitoring.
• Adherence to recommended management strategies ensures the well-being of both mother and neonate.